Lung transplant is the only therapy for several end-stage lung diseases; however, the number of donated lungs suitable for transplant is not sufficient, and hundreds of patients have died waiting for an organ. Ex vivo lung perfusion (EVLP) has emerged as a new technology with the potential of reconditioning human donor lungs previously unsuitable for transplantation. Since the first successful transplant of a lung treated using EVLP in the year 2000, multiple clinical trials have demonstrated, in several transplant centers around the word, the feasibility and the potential of EVLP to increase the total number of lungs available for transplant.
From the *Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; *The Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, Division of Pulmonary, Allergy, and Critical Care Medicine Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; † and ‡McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Submitted for consideration March 2017; accepted for publication in revised form June 2017.
This work was supported by grant from 1 R01 HL123766-01A1 and W81XWH-15-2-0072 14017001.
Disclosure: The authors have no conflicts of interest to report.
Correspondence: Mauricio Rojas, Division of Pulmonary, Allergy, and Critical Care Medicine. Department of Medicine, University of Pittsburgh, W1244 BST Tower, 200 Lothrop Street, Pittsburgh, PA 15261. Email: firstname.lastname@example.org.